Biotech/Pharmaceuticals

Strong Enbrel Sales Help Immunex Match Estimates

10/17/01 - 06:27 PM EDT


Updated from 5:26 p.m. EDT

Biopharmaceutical firm Immunex IMNX matched Wall Street estimates for the third quarter, posting earnings of 7 cents per share on strong sales of its rheumatoid arthritis drug, Enbrel.

Net income for the third quarter rose 26% to $39.7 million, or 7 cents per share, compared to $31.5 million, or 6 cents per share, in the third quarter last year.

Enbrel sales in the quarter totaled $198.1 million, up 15% compared to the same period last year. That figure was on the higher end of company guidance and within the range expected by Wall Street analysts.

On the company's conference call, Immunex officials forecast fourth quarter Enbrel sales of between $205 million and $215 million -- enough to meet its previously stated goal of $750 million in 2001 sales of the drug. Immunex has been under pressure all year to overcome a supply crunch for the drug. In August, the company announced several agreements with manufacturing partners to boost Enbrel supplies. Immunex also said it's still on track to get a new company-owned plant in operation during the second half of 2002.

Wednesday, the company reiterated its previous forecast that this new manufacturing capacity will contribute to 2002 Enbrel sales of between $900 million and $1.3 billion. Immunex is hoping to expand use of the drug into other diseases like psoriatic arthritis and psoriasis.

Total revenue for the quarter reached $253 million, compared to $219 million in the year-ago quarter.

Immunex shares fell $1.84, or almost 8%, to $21.34 in Wednesday trading, before earnings were announced.


Headlines & Perspectives

Biotech/Pharmaceuticals

Go To Section Home


04/28/08
Cramer's Take on the Top 10 Searched Stocks

Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.


04/26/08
Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.


04/26/08
Coming Week: Make or Break

Investors will have to deal with a Fed meeting and another flood of earnings and economic data.


04/27/08
This Week's Barron's Roundup

Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.


04/28/08
Monday's Analysts' Upgrades, Downgrades

See who made what calls.


02/29/08
3 Stocks I Saw On TV

3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA


04/28/08
One Bank Pick Stumbles, the Other Soars

TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.


04/28/08
Grand Theft Auto IV Hits the Jackpot

Take-Two's latest hit receives a perfect score from industry reviewers.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!